Mersana, Janssen partner to discover new ADC product candidates
Mersana and Janssen Biotech have signed research collaboration and license agreement to discover antibody-drug conjugates (ADCs) for three targets.
Synaffix Glycoconnect News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Synaffix Glycoconnect. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Synaffix Glycoconnect Today - Breaking & Trending Today
Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
/PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug...
Source: prnewswire.com
Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
/PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug...
Source: prnewswire.com